Home > Oncology > ASCO 2020 > COVID-19 & Telemedicine > COVID-19 and Cancer Consortium Registry: initial results

COVID-19 and Cancer Consortium Registry: initial results

Presented By
Prof. Jeremy L. Warner, Vanderbilt-Ingram Cancer Center, USA
Conference
ASCO 2020
Trial
COVID-19 and Cancer Consortium Registry (CCC19)
Featured video: Data from the COVID-19 and Cancer Consortium (CCC19) examining mortality and severe illness among patients with cancer who have contracted COVID-19, and use of azithromycin and hydroxychloroquine. [embed]https://vimeo.com/440617556[/embed] In a registry of cancer patients with COVID-19, older age, poor performance status, and progressing cancer were strongly associated with increased mortality, especially in subsets admitted to the ICU and/or intubated. Jeremy L. Warner (Vanderbilt-Ingram Cancer Center, USA) presented the initial results from the COVID-19 and Cancer Consortium Registry (CCC19) [1]. The effects of COVID-19 on patients with cancer are poorly understood. Currently, published reports are limited by small patient cohorts and lack of systematic reporting. A real-world registry capturing data acro...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on